Abeona Therapeutics Inc Bennfentes tulajdonlás
Mi az Abeona Therapeutics Inc Bennfentes tulajdonlás?
A Bennfentes tulajdonlás az Abeona Therapeutics Inc - 11.37%
Mi a Bennfentes tulajdonlás meghatározása?
A bennfentes tulajdonjog kiszámítása a bennfentesek tulajdonában lévő részvények (részvényesek, akik a vállalat több mint 5% -át, vagy a vállalat tisztségviselőjét vagy igazgatóját birtokolják) teljes létszámával, osztva a teljes részvénykivonással.
A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.
A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.
Bennfentes tulajdonlás a Health Care szektor a NASDAQ-on cégekben a Abeona Therapeutics Inc -hoz képest
Mit csinál Abeona Therapeutics Inc?
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
bennfentes tulajdonlás -hoz hasonló cégek Abeona Therapeutics Inc
- Ramaco Resources Inc nak Bennfentes tulajdonlás 11.36% van
- QMC Quantum Minerals Corp nak Bennfentes tulajdonlás 11.36% van
- Catalyst Biosciences Inc nak Bennfentes tulajdonlás 11.36% van
- Palantir Technologies nak Bennfentes tulajdonlás 11.36% van
- Zenith nak Bennfentes tulajdonlás 11.37% van
- Aptitude Software plc nak Bennfentes tulajdonlás 11.37% van
- Abeona Therapeutics Inc nak Bennfentes tulajdonlás 11.37% van
- Life360 nak Bennfentes tulajdonlás 11.38% van
- Dalata Hotel plc nak Bennfentes tulajdonlás 11.38% van
- Roth CH Acquisition I Co nak Bennfentes tulajdonlás 11.38% van
- Copper Lake Resources nak Bennfentes tulajdonlás 11.38% van
- Copper Lake Resources nak Bennfentes tulajdonlás 11.38% van
- SBI nak Bennfentes tulajdonlás 11.39% van